[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tree-nut-allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tree-nut-allergy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100587635","the-nacho-trial-nut-allergy-children-oit-100587635",false,"NCT06930950","The NACHO Trial (Nut Allergy Children OIT)","Efficacy of Oral Immunotherapy for Cashew Allergy in Children Aged 1 to 17 Years: a Clinical Prospective Randomized Controlled Interventional Trial","Inclusion Criteria:\n\n1. Age 6 months - 17 years\n2. Sensitization to cashew nut (allergen-specific IgE or positive skin PRICK test)\n3. Positive oral food challenge for cashew nut\n\nExclusion Criteria:\n\n1. Poor adherence\n2. Uncontrolled or severe asthma\n3. Uncontrolled active or severe or atopic dermatitis\n4. Chronic urticaria\n5. Eosinophilic esophagitis or other gastrointestinal eosinophilic disorders\n6. Active malignant neoplasia\n7. Active systemic, autoimmune disease\n8. Diabetes treated with insulin\n9. Severe systemic illness or severe medical conditions such as cardiovascular or lung diseases\n10. Medication with beta blockers\n11. Medication with ACE-inhibitors\n12. Mastocytosis\n13. Pregnancy or breastfeeding\n14. Language barriers (not fluent Finnish or Swedish)","ALL","1 Year","17 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"NA","Most food allergies that begin in early childhood are mild and resolve by school age, but nut allergies persist in about 80-90% of individuals into adulthood. The consumption of nuts, particularly cashew nuts, has increased dramatically in Finland in the 21st century, leading to a rise in severe allergic reactions to cashew nuts among young children. Of the food anaphylaxis cases reported in the Finnish Anaphylaxis Registry between 2015-2020, 49% were caused by nuts, with cashew nuts being the most common trigger. The standard treatment for nut allergies is strict avoidance of nuts and symptom management with emergency medications.\n\nOral immunotherapy (OIT) is a food allergy treatment that increases tolerance, and it has primarily been studied in school-aged children, with desensitization achieved in about 80% of cases. Permanent tolerance, depending on the allergen, develops in 30-50% of cases within five years. International guidelines recommend peanut OIT for children over the age of 4 who have severe peanut allergies. The likelihood of achieving tolerance, especially permanent tolerance, appears to improve the earlier the treatment is started. To date, only one study (NUIT CRACKER) has been published on cashew nut desensitization in children over 4 years old, involving 50 children, where 88% achieved desensitization to both cashew nuts and pistachios.\n\nThe aim of this study is to develop a cashew nut desensitization protocol and investigate its effectiveness in achieving tolerance and permanent desensitization in children aged 1-17 years, compared to cashew nut avoidance. The study will assess the safety of cashew nut desensitization and its impact on the quality of life of patients and their families.",[27,28,29],"Oral Immunotherapy for Food Allergy","Tree Nut Allergy","Cashew Nut Allergy",[31,32,33,34],"Oral immunotherapy","Cashew","Tree Nut","Food allergen immunotherapy","RECRUITING","2025-04-09",{"date":38,"type":39},"2025-04-16","ACTUAL",{"date":41,"type":39},"2024-09-13",{"date":43,"type":21},"2029-11-05",{"name":45,"class":46},"HUS Skin and Allergy Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100519013","thresholds-in-food-allergy-evaluation-and-prediction-100519013","NCT06038019","Thresholds In Food Allergy evaluaTion And predictioN","Thresholds In Food Allergy evaluaTion And predictioN, a Prospective, Multicentre Registry Study","TITAN","Inclusion Criteria:\n\n1. Suspicion or history of food allergy based on medical history, positive skin prick test, and\u002For serum food-specific IgE. A suggestive history is defined as typical clinical signs and\u002For symptoms (urticaria, angioedema, abdominal pain, vomiting, dyspnea, wheeze) within 60 minutes of the ingestion of a food.\n2. Ability to discontinue all antihistamines for 1 week before oral food challenge.\n\nExclusion Criteria:\n\n1. Previous desensitization treatment to a food allergen\n2. Allergies to any component of the oral challenge vehicle\n3. Unstable conditions including uncontrolled asthma or chronic urticaria\n4. Any clinically significant disease\u002Fchronic medical condition which may interfere with study evaluations.",true,"3 Months","65 Years",{"count":60,"type":21},2000,"1 Day","OBSERVATIONAL","Thresholds In food allergy evaluaTion And predictioN, a prospective, observational registry. The aim is to quantify food allergy thresholds in Canada and their clinical predictors.",[28,65],"Food Allergy",[67,65,68,69],"Immunotherapy","Diagnosis","Prognosis","2024-05-30",{"date":72,"type":39},"2024-06-03",{"date":74,"type":39},"2023-11-01",{"date":76,"type":21},"2051-01-01",{"name":78,"class":46},"Hamilton Health Sciences Corporation",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100479340","trade-trial---tree-nut-immunotherapy-route-development-and-evaluation-100479340","NCT05521711","TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation","TRADE","Inclusion Criteria:\n\n* Allergic to tree nut with baseline threshold of 444 mg protein or less and provides consent, and where applicable, assent.\n\nExclusion Criteria:\n\n1. History of anaphylaxis to tree nut severe enough to cause shock, syncope, or intubation\n2. Eosinophilic or other inflammatory gastrointestinal disease within the past 2 years\n3. Severe (GINA severity class 5) or uncontrolled asthma including exacerbation within past 6 months\n4. Use of biologics, other food immunotherapy or experimental treatment in past 6 months.\n5. Ongoing other allergic diseases severe enough to preclude discontinuing antihistamines for 7 days prior to assessment visits\n6. Pregnancy or significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease; allergy to the oat-based placebo) which would put the participant at excessive risk for food allergic reactions as judged by local investigator","16 Years",{"count":88,"type":21},60,[24],"Tree nut immunotherapy Route Assessment and DEvelopment (TRADE) is a randomized controlled trial that evaluates the efficacy and safety of sublingual immunotherapy and lower, more tolerable, doses of oral immunotherapy than currently in use.",[28,65],[67,93],"Randomized Controlled Trial (RCT)",{"date":72,"type":39},{"date":96,"type":39},"2023-09-01",{"date":98,"type":21},"2027-01-01",{"name":78,"class":46}]